TB-500 (Thymosin Beta-4) Side Effects: Safety Profile
TB-500 is commonly described as a fragment or derivative associated with thymosin beta-4 biology and is marketed for repair and recovery. Human clinical evidence for these promoted uses is lacking: tissue-repair findings come from preclinical models, human orthopaedic data are absent, and TB-500/TB-4 remain banned substances in sport.
TB-500 is commonly described as a fragment or derivative associated with thymosin beta-4 biology and is marketed for repair and recovery. Human clinical evidence for these promoted uses is lacking: tissue-repair findings come from preclinical models, human orthopaedic data are absent, and TB-500/TB-4 remain banned substances in sport.
Key Takeaways
- TB-500 is not FDA-approved for recovery or performance uses.
- Its repair claims rest on preclinical (animal) data, human orthopaedic evidence is lacking.
- Side effects are not well defined; injection reactions, immune effects, impurities, and unknown long-term risks are the main concerns.
- There are theoretical concerns about angiogenesis and unwanted tissue growth, though human risk is not characterised.
- TB-500/TB-4 are banned substances in sport, athletes should verify anti-doping rules before any exposure.
TB-500 at a Glance
| Property | Detail |
|---|---|
| Full name | TB-500, marketed as a fragment/derivative associated with thymosin beta-4 (TB-4) |
| Type | Synthetic peptide |
| FDA approval status | Not approved for marketed recovery or performance uses |
| Promoted uses | Tissue repair, tendon/ligament recovery, not validated in humans |
| Evidence base | Preclinical/animal models; human orthopaedic data lacking |
| Anti-doping status | Banned substance in sport (TB-4/TB-500) |
TB-500 Side Effects: What Is Known
Because controlled human trials are lacking, TB-500 side effects are not well characterised. The domains below reflect risks common to injected peptides plus mechanism-based theoretical concerns.
| Side Effect Domain | What May Occur | Why It Matters |
|---|---|---|
| Injection-site reactions | Pain, redness, swelling, bruising | Common to injected peptides; may signal irritation or contamination |
| Infection | Warmth, pus, fever, cellulitis, abscess | Non-sterile technique or contaminated product can cause serious infection |
| Immune / allergic reactions | Rash, hives, swelling, difficulty breathing | Peptides and impurities can trigger immune reactions |
| Angiogenesis / tissue growth | Theoretical stimulation of unwanted growth | Pro-angiogenic activity in animal models; long-term human impact unknown |
| Long-term effects | Unknown | No long-term human studies exist |
| Anti-doping violation | Failed drug test, sanctions | TB-500/TB-4 are prohibited in sport |
Using TB-500 with other medications or supplements?
Check it against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
Safety Profile in Detail
| Dimension | Research summary |
|---|---|
| Mechanism | Proposed mechanisms include angiogenesis, cell migration, and tissue-repair pathways, mostly based on preclinical data. |
| Clinical evidence | Human evidence for injury-recovery claims is insufficient; reviews emphasise a lack of reliable clinical data. |
| Severity | Unknown. Potential concerns include injection reactions, immune reactions, effects on abnormal tissue growth/angiogenesis, contamination, and anti-doping violations. |
| Symptoms to watch | Injection-site infection, swelling, rash, fever, unusual bruising, unexplained growths, worsening pain, or systemic allergic symptoms. |
| Official guidance | Not FDA-approved for marketed recovery/performance uses. Sports-medicine literature warns that indications, dosing, frequency, and duration are unknown. |
| Practical patient advice | Avoid self-injection. Athletes should treat TB-500 as a doping-risk substance and verify anti-doping rules. |
Common Questions About TB-500 Side Effects
No high-quality human evidence proves clinical benefit for common marketed uses.
They are not well defined; injection reactions, immune effects, impurities, and unknown long-term risks are concerns.
Reviews note TB-4/TB-500 remain banned substances in sports.
Products marketed as TB-500 may not be equivalent in purity, formulation, or pharmacology to studied compounds.
Theoretical concerns exist around angiogenesis/tissue growth, but human risk is not well characterised.
Check TB-500 against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. fda.gov.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- European Medicines Agency. Product information and EPARs. ema.europa.eu.